Related Experiment Video

Updated: May 2, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

9.7K

Estrogen receptor mutations in breast cancer--new focus on an old target

Corrinne V Segal1, Mitch Dowsett

  • 1Authors' Affiliations: Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research and Academic Department of Biochemistry, The Royal Marsden Hospital, London, United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 4, 2014
PubMed

Insights

New estrogen receptor-1 (ESR1) mutations emerge in metastatic breast cancer, often missed in early diagnosis. While some mutants respond to anti-estrogen drugs, novel therapies are needed for effective treatment.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Estrogen receptor-positive (ER+) breast cancer is a major health concern.
  • Metastatic breast cancer presents unique therapeutic challenges.
  • Emergence of ESR1 mutations is increasingly recognized in advanced disease.

Purpose of the Study:

  • To investigate the prevalence and characteristics of ESR1 mutations in ER+ metastatic breast cancer.
  • To assess the sensitivity of ESR1 mutants to existing anti-estrogen therapies.
  • To identify the need for novel therapeutic strategies targeting these mutations.

Main Methods:

  • Genomic analysis of tumor samples from patients with metastatic breast cancer.
  • Functional assays to determine the activity of identified ESR1 mutants.
  • Pharmacological profiling of ESR1 mutants against standard therapies.

Main Results:

  • Substantial numbers of constitutively active ESR1 mutations were detected in metastatic breast cancer.
  • These mutations were largely absent in primary tumors.
  • Some ESR1 mutants exhibited partial sensitivity to current anti-estrogen treatments.

Conclusions:

  • ESR1 mutations represent a significant mechanism of resistance and adaptation in ER+ metastatic breast cancer.
  • Current anti-estrogen therapies may have limited efficacy against certain ESR1 mutants.
  • Development of novel therapeutics is crucial for overcoming resistance driven by ESR1 mutations.

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

23.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K